1. Home
  2. ARVN vs RNST Comparison

ARVN vs RNST Comparison

Compare ARVN & RNST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARVN
  • RNST
  • Stock Information
  • Founded
  • ARVN 2015
  • RNST 1904
  • Country
  • ARVN United States
  • RNST United States
  • Employees
  • ARVN N/A
  • RNST N/A
  • Industry
  • ARVN Biotechnology: Pharmaceutical Preparations
  • RNST Major Banks
  • Sector
  • ARVN Health Care
  • RNST Finance
  • Exchange
  • ARVN Nasdaq
  • RNST Nasdaq
  • Market Cap
  • ARVN 456.2M
  • RNST 3.7B
  • IPO Year
  • ARVN 2018
  • RNST N/A
  • Fundamental
  • Price
  • ARVN $7.61
  • RNST $37.78
  • Analyst Decision
  • ARVN Buy
  • RNST Buy
  • Analyst Count
  • ARVN 22
  • RNST 6
  • Target Price
  • ARVN $20.02
  • RNST $42.20
  • AVG Volume (30 Days)
  • ARVN 1.3M
  • RNST 515.2K
  • Earning Date
  • ARVN 10-29-2025
  • RNST 10-21-2025
  • Dividend Yield
  • ARVN N/A
  • RNST 2.33%
  • EPS Growth
  • ARVN N/A
  • RNST N/A
  • EPS
  • ARVN N/A
  • RNST 2.24
  • Revenue
  • ARVN $372,800,000.00
  • RNST $735,575,000.00
  • Revenue This Year
  • ARVN $1.61
  • RNST $42.66
  • Revenue Next Year
  • ARVN N/A
  • RNST $12.60
  • P/E Ratio
  • ARVN N/A
  • RNST $16.86
  • Revenue Growth
  • ARVN 299.57
  • RNST 17.23
  • 52 Week Low
  • ARVN $5.90
  • RNST $26.97
  • 52 Week High
  • ARVN $29.61
  • RNST $40.40
  • Technical
  • Relative Strength Index (RSI)
  • ARVN 49.90
  • RNST 45.88
  • Support Level
  • ARVN $7.58
  • RNST $37.10
  • Resistance Level
  • ARVN $7.89
  • RNST $39.10
  • Average True Range (ATR)
  • ARVN 0.37
  • RNST 0.87
  • MACD
  • ARVN -0.03
  • RNST -0.23
  • Stochastic Oscillator
  • ARVN 18.42
  • RNST 20.61

About ARVN Arvinas Inc.

Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

About RNST Renasant Corporation

Renasant Corp operates as a holding company for Renasant Bank, a Mississippi banking corporation, and its subsidiary, Renasant Insurance, Inc. It has three reportable segments: Community banks, Insurance, and Wealth management. With its Community banks segment, the company provides a range of financial services to individuals and small businesses. Its Insurance segment is an insurance agency providing commercial and personal insurance through third-party carriers. The Wealth management segment provides a range of services, including money management and retirement planning. The majority of the company's revenue is driven by lending activities in its community banks segment.

Share on Social Networks: